Dyne Therapeutics

Company snapshot

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical pro

• 1 approved product(s) across US/EU regulatory metadata.
• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 82 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Dyne Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Dyne Therapeutics.

1. Jun 8, 2026 Clinical update

   DYNE-101 for Myotonic Dystrophy Type 1 — Phase 2

2. Jun 8, 2026 Clinical update

   DYNE251-DMD-201 — Phase 2

3. Jun 8, 2026 Clinical update

   SODIUM CHLORIDE , DYNE-101 — Phase 3

4. Jun 5, 2026 Clinical update

   zeleciment basivarsen (DYNE-101) — Phase 3

5. Jun 5, 2026 Clinical update

   DYNE-251 — Phase 2

View all clinical trial activity →

• What is Dyne Therapeutics?

  Dyne Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker DYN. Primary therapeutic focus areas include Myotonic Dystrophy Type 1, Myotonic Dystrophy Type 1 (DM1), Duchenne muscular dystrophy, Duchenne Muscular Dystrophy (DMD). NovaPh

• Is Dyne Therapeutics publicly traded?

  Yes. Dyne Therapeutics is listed with ticker DYN on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Dyne Therapeutics develop or market?

  We link 11 drug profile(s) where Dyne Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/dyne-therapeutics#company-drugs.

• What are the latest developments for Dyne Therapeutics?

  In the last 12 months our linked public records show 6 trial program update(s) and 9 US patent grant(s) tied to this profile.

• What therapeutic areas does Dyne Therapeutics focus on?

  Dyne Therapeutics focuses on Myotonic Dystrophy Type 1, Myotonic Dystrophy Type 1 (DM1), Duchenne muscular dystrophy based on our analysis of their pipeline programs and drug development activities.